Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|11|2|137-144

ISSN： 1574-8863

Source： Current Drug Safety, Vol.11, Iss.2, 2016-04, pp. : 137-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion‐dependent thalassemia: A randomized controlled trial

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : 262-268

John Wiley & Sons Inc

Access to resources Recommend Favorite

Activity of cytochrome P450 1A2 in relation to hepatic iron accumulation in transfusion‐dependent β‐thalassaemia major patients

By  

VOX SANGUINIS, Vol. 108, Iss. 3, 2015-04 ,pp. : 268-273

John Wiley & Sons Inc

Access to resources Recommend Favorite

Deferasirox effect on renal haemodynamic parameters in patients with transfusion‐dependent β thalassaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 882-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia

By  

Acta Haematologica, Vol. 137, Iss. 1, 2016-11 ,pp. : 20-26

Karger

Access to resources Recommend Favorite

Combination therapy with a Tmprss6RNAi‐therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β‐thalassemia intermedia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 310-313

John Wiley & Sons Inc

Access to resources Recommend Favorite